GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (OTCPK:RGTLF) » Definitions » Short Percentage of Float

RGTLF (Argent Biopharma) Short Percentage of Float


View and export this data going back to 2017. Start your Free Trial

What is Argent Biopharma Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Argent Biopharma's Short Percentage of Float

For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Argent Biopharma's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Argent Biopharma's Short Percentage of Float falls into.


;
;

Argent Biopharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (OTCPK:RGTLF) » Definitions » Short Percentage of Float
Comparable Companies
ASX:EOF ASX:IVX ASX:AGH ASX:EXL ASX:PER ASX:CAN ASX:BP8 ASX:ECS ASX:NXS ASX:LGP ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
H5O0:Germany RGT:Australia
Address
295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Website
https://www.argentbiopharma.com
Argent Biopharma Ltd is a drug discovery company that addresses unmet medical needs. The company focuses on multidisciplinary methods with nanotechnology, developing multi-target therapies for comprehensive disease management, especially in the central nervous system and immunology treatments. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury, and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others.